菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Locations & Facilities

Global Network

  • Dundalk, Ireland

    Supported by the Irish Government and IDA Ireland, construction of the manufacturing facilities began in 2018 with operations commencing in 2021

    Located in Dundalk, Co. Louth, mid-way between Dublin and Belfast, this 26-hectare site is less than an hour’s drive from Ireland’s two largest cities

    This “Factory of the Future” will create 400 jobs and provide commercial biologics manufacturing services

    2023 ISPE Facility of the Year Award for Operations

  • WuXi Vaccines

    The site is adjacent to the WuXi Biologics “Factory of the Future”

    Capabilities at the site will include drug substance and drug product manufacture and quality control

    QC potency lab received GMP certificate in 2022 from the Ireland Health Products Regulatory Authority

  • Leverkusen, Germany

    Over 13,000 sq. m. drug product fill & finish facility (DP7)

    Liquid and lyophilization annual fill capacity of 10 million doses

    Acquired from Bayer in April 2020 and released for GMP manufacturing in the same year

  • Wuppertal, Germany

    30,000 sq. m. drug substance manufacturing facility (MFG19)

    38 km (30 minutes driving) from the WuXi Biologics drug product fill & finish facility in Leverkusen (DP7) – both sites will support WuXi Biologics’ “Global Dual Source” strategy

    Acquired from Bayer in May 2021

  • Massachusetts, U.S.

    Over 189,500 sq. ft. drug substance manufacturing facility (MFG11) featuring state-of-the-art single-use technology located within The Reactory biomanufacturing park in Worcester, MA

    Dedicated to biologics clinical- and commercial-scale drug substance cGMP manufacturing with total bioreactor capacity of 36,000L

    Site has completed weather tight status; facility to be operational in 2025 with GMP-release expected in 2026

  • New Jersey, U.S.

    Over 154,400 sq. ft. of laboratories and manufacturing suites located in the robust biopharmaceutical tristate region of NY, NJ and PA

    Services include biologics CMC development and clinical-scale drug substance and drug product cGMP manufacturing

    Site operations commenced in 2021

    Drug substance manufacturing facility (MFG18) GMP release in 2022

    Robotic drug product fill and cGMP manufacturing facility (DP12) operations and GMP release expected in 2024

  • Pennsylvania, U.S.

    More than 33,000 sq. ft. facility located in the Discovery Labs campus in King of Prussia (KOP), PA

    Services include biologics process development and process characterization

    Biosafety Level 2 laboratories

    Operational since 2020

  • Boston Research

    Service Center, U.S.

    Boston Research Service Center, located within ABI-LAB in Natick, provides biologics discovery services

    Capabilities include antibody-based drug discovery through hybridoma, high-throughput screening, in vitro pharmacology, small scale protein production, and cell line development for research

    Operational since 2023

  • Shanghai, China Waigaoqiao Free Trade Zone

    The site offers comprehensive, integrated one-stop biologics discovery, development and clinical manufacturing services in one central location

    European Medicines Agency (EMA)-certified GMP cell banking suites

    200,000 sq. ft. clinical drug substance manufacturing facility (MFG3) has been operational since 2018

  • Shanghai, China Fengxian District

    1.6 million sq. ft. Integrated Biologics CRDMO center

    The Center provides biologics discovery, development and clinical GMP manufacturing services in one location

    Operational since 2021

  • Shanghai, China Lin-gang Special Area

    8,000 sq. m. Biosafety Testing Center

    Capabilities include cell bank characterization, unprocessed bulk harvest, virus harvest, and raw materials of animal origin release testing as well as viral clearance studies

    Operational since 2022

  • Wuxi, China Mashan

    Multiple drug substance and drug product manufacturing facilities (MFG1, MFG2, MFG4, MFG5, DP1, DP2, DP4, DP5) located in this region with a total facility footprint of 160,000 sq. m.

    Capabilities include early and late-stage process development and clinical & commercial-scale drug substance and drug product GMP manufacturing

    First biologics facility in China approved by the U.S. FDA and EMA for commercial manufacturing

  • WuXi XDC Wuxi Hi-Tech District

    6,000 sq. m. site dedicated to the development and GMP manufacturing of Antibody Drug Conjugates (ADCs) and other bioconjugates.

    Capabilities include process development, pilot scale to large-scale cGMP manufacturing of drug substance and drug product.

    GMP release of this facility commenced in 2019

  • Suzhou, China Wuzhong District

    Over 16,000 sq. m. Biosafety Testing Center, one of the first third-party centers for biosafety testing services in Asia

    Services include cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials as well as viral clearance per global regulatory guidelines.

    Operational since 2014

  • Suzhou, China Suzhou Industrial Park

    Site contains a drug substance manufacturing facility (MFG21) and drug product fill & finish facility (DP11)

    Services include process development, clinical drug substance manufacturing as well as liquid and lyophilization drug product fills

    Site acquired from CMAB Biopharma Group and released for GMP manufacturing in 2021

  • Hangzhou, China Economic & Technological Development Zone

    35,000 sq. m. Biologics Integrated Innovation Center

    The center serves the development and GMP manufacturing of microbial-derived products and mRNA products

    Operational since 2020

    The site includes drug substance manufacturing facility (MFG14) and drug product fill & finish facility (DP8), which were released for GMP manufacturing in 2022

  • Hangzhou, China Economic & Technological Development Zone

    50,400 sq. m. manufacturing site that includes a drug substance manufacturing facility (MFG20) and drug product fill & finish facilities (DP9 and DP10)

    Facilities acquired from Pfizer China and were released for GMP manufacturing in 2021

  • Chengdu, China New Expansion Sites

    314,000 sq. m. site, WuXi Biologics’ largest site in Southwest China

    The Protein Science labs at this site were launched in November 2022

    The initial bioreactor capacity of 48,000L for drug substance GMP manufacturing is expected to be available in 2024

  • Hebei, China Hi-Tech Industrial Development Zone

    82,160 sq. m. site, one of the largest biologics CRDMO sites in northern China

    The site flexibly provides commercial manufacturing services at 4,000L to 20,000L scale

    Drug substance manufacturing facility (MFG8) GMP release commenced in 2022

  • Singapore New Expansion Sites

    USD$1.4 billion investment over ten years to build a comprehensive CRDMO Center

    The Center will provide end-to-end services from biologics research and development to large-scale drug substance and drug product GMP manufacturing

    120,000 liters biomanufacturing capacity is expected to be available in 2026